Medicare Part D drugs starting with D
121 drugs start with D; 53 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Dupixent in 2024: $2.5 billion, what plans and patients paid at the pharmacy before rebates.
Which drugs start with D?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Dabigatran etexilate | 98.7% | Tier 4 | $76 million |
| Dalbavancin | 2.2% | Tier 5 | no 2024 match |
| Dalfampridine | 83.1% | Tier 3 | $48 million |
| Daliresp (roflumilast) | 0.1% | Tier 4 | $5 million |
| Dalvance (dalbavancin) | 2.3% | Tier 5 | $18 million |
| Danazol | 100% | Tier 4 | $2 million |
| Dantrium (dantrolene sodium) | under 0.1% | Tier 1 | $8 thousand |
| Dantrolene sodium | 78% | Tier 4 | $4 million |
| Danziten (nilotinib) | 96.7% | Tier 5 | no 2024 match |
| Dapagliflozin | 100% | Tier 3 | $202 million |
| Dapagliflozin / metformin hydrochloride | 0.6% | Tier 4 | $6 million |
| Dapsone | 100% | Tier 3 | $8 million |
| Daptacel (DTaP vaccine) | 100% | Tier 1 | $16 thousand |
| Daptomycin | 100% | Tier 5 | $121 million |
| Daraprim (pyrimethamine) | under 0.1% | Tier 1 | no 2024 match |
| Darifenacin | 15.5% | Tier 4 | $7 million |
| Darunavir | 100% | Tier 4 | $44 million |
| Dasatinib | 100% | Tier 5 | $50 million |
| Daurismo (glasdegib) | 100% | Tier 5 | $4 million |
| Dawnzera (donidalorsen) | 0.7% | Tier 5 | no 2024 match |
| Daybue (trofinetide) | 4.6% | Tier 5 | $40 million |
| Dayvigo (lemborexant) | 32.1% | Tier 3 | $21 million |
| DDAVP (desmopressin acetate) | under 0.1% | Tier 1 | $348 thousand |
| Deblitane (norethindrone) | 95.4% | Tier 2 | $42 thousand |
| Deferasirox | 100% | Tier 3 | $30 million |
| Deferiprone | 13.2% | Tier 5 | $7 million |
| Deflazacort | 16.5% | Tier 5 | $1 million |
| Delestrogen (estradiol valerate) | 0.2% | Tier 4 | $77 thousand |
| Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) | 100% | Tier 5 | $18 million |
| Demeclocycline hydrochloride | 44.9% | Tier 4 | $4 million |
| Demerol (meperidine hydrochloride) | 0.1% | Tier 4 | $33 thousand |
| Denavir (penciclovir) | 0.3% | Tier 4 | $466 thousand |
| Depakote (divalproex sodium) | 0.2% | Tier 1 | $25 million |
| Depen (penicillamine) | under 0.1% | Tier 1 | no 2024 match |
| Depo-estradiol (estradiol cypionate) | 43.6% | Tier 4 | $670 thousand |
| Depo-Provera (medroxyprogesterone acetate) | 0.5% | Tier 3 | $10 thousand |
| depo-subQ provera (medroxyprogesterone acetate) | 100% | Tier 3 | $53 thousand |
| Depo-testosterone (testosterone cypionate) | 26.7% | Tier 3 | $162 thousand |
| Dermotic (fluocinolone acetonide) | 0.5% | Tier 3 | $36 thousand |
| Descovy (emtricitabine / tenofovir alafenamide) | 100% | Tier 5 | $545 million |
Show the other 81 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Desipramine hydrochloride | 100% | Tier 4 | $3 million |
| Desloratadine | 74.6% | Tier 2 | $7 million |
| Desmopressin acetate | 100% | Tier 3 | $15 million |
| Desonide | 81.9% | Tier 4 | $10 million |
| Desoximetasone | 58.7% | Tier 4 | $3 million |
| Desvenlafaxine | 9.4% | Tier 4 | $2 million |
| Desvenlafaxine succinate | 100% | Tier 2 | $61 million |
| Dexamethasone | 100% | Tier 2 | $22 million |
| Dexamethasone / neomycin / polymyxin b | 100% | Tier 2 | $14 million |
| Dexamethasone / tobramycin | 100% | Tier 3 | $23 million |
| Dexamethasone phosphate | 99.9% | Tier 2 | no 2024 match |
| Dexedrine (dextroamphetamine sulfate) | under 0.1% | Tier 1 | $509 thousand |
| Dexlansoprazole | 41.6% | Tier 4 | $220 million |
| Dexmethylphenidate hydrochloride | 91.7% | Tier 3 | $5 million |
| Dextroamphetamine sulfate | 78.3% | Tier 4 | $9 million |
| Diacomit (stiripentol) | 100% | Tier 5 | $2 million |
| Diazepam | 100% | Tier 2 | $19 million |
| Diazoxide | 100% | Tier 5 | $3 million |
| Dichlorphenamide | 2.7% | Tier 5 | $723 thousand |
| Diclofenac epolamine | 5.2% | Tier 4 | $112 million |
| Diclofenac potassium | 96.6% | Tier 2 | $73 million |
| Diclofenac sodium | 100% | Tier 2 | $353 million |
| Diclofenac sodium / misoprostol | 34.9% | Tier 4 | $6 million |
| Dicloxacillin | 100% | Tier 2 | $984 thousand |
| Dicyclomine hydrochloride | 100% | Tier 2 | $43 million |
| Dificid (fidaxomicin) | 89.4% | Tier 5 | $154 million |
| Diflorasone diacetate | 7.5% | Tier 4 | $18 million |
| Diflucan (fluconazole) | 0.2% | Tier 1 | $335 thousand |
| Diflunisal | 72.2% | Tier 2 | $713 thousand |
| Difluprednate | 52.6% | Tier 4 | $14 million |
| Digoxin | 100% | Tier 2 | $37 million |
| Dihydroergotamine mesylate | 100% | Tier 5 | $23 million |
| Dilantin (phenytoin) | 100% | Tier 4 | $30 million |
| Dilt (diltiazem hydrochloride) | 99.7% | Tier 2 | $14 million |
| Diltiazem hydrochloride | 100% | Tier 2 | $17 million |
| Dimethyl fumarate | 73.2% | Tier 4 | $67 million |
| Diovan (valsartan) | under 0.1% | Tier 1 | $21 million |
| Diovan HCT (hydrochlorothiazide / valsartan) | under 0.1% | Tier 1 | $6 million |
| Dipentum (olsalazine sodium) | 5.6% | Tier 5 | $3 million |
| Diprolene (augmented betamethasone) | under 0.1% | Tier 1 | $13 thousand |
| Dipyridamole | 55.5% | Tier 2 | $1 million |
| Disopyramide | 45.4% | Tier 4 | $2 million |
| Disulfiram | 100% | Tier 2 | $2 million |
| Divalproex sodium | 100% | Tier 2 | $216 million |
| Divigel (estradiol) | under 0.1% | Tier 1 | $623 thousand |
| Dofetilide | 100% | Tier 4 | $67 million |
| Dojolvi (triheptanoin) | 1.4% | Tier 5 | $3 million |
| Dolishale (ethinyl estradiol / levonorgestrel) | 69.9% | Tier 2 | $14 thousand |
| Dolobid (diflunisal) | 2.3% | Tier 5 | $671 thousand |
| Donepezil hydrochloride | 100% | Tier 1 | $100 million |
| Donepezil hydrochloride / memantine hydrochloride | 40.5% | Tier 3 | no 2024 match |
| Doptelet (avatrombopag) | 64.2% | Tier 5 | $160 million |
| Dorzolamide | 100% | Tier 2 | $22 million |
| Dorzolamide / timolol | 100% | Tier 2 | $78 million |
| Dotti (estradiol) | 76.7% | Tier 3 | $13 million |
| Dovato (dolutegravir / lamivudine) | 100% | Tier 5 | $541 million |
| Doxazosin | 100% | Tier 1 | $36 million |
| Doxepin | 100% | Tier 2 | $66 million |
| Doxepin hydrochloride | 14.9% | Tier 4 | no 2024 match |
| Doxercalciferol | 58.9% | Tier 4 | $617 thousand |
| Doxy (doxycycline hyclate) | 97.3% | Tier 4 | $212 thousand |
| Doxycycline anhydrous | 17.2% | Tier 4 | no 2024 match |
| Doxycycline hyclate | 99.8% | Tier 2 | $82 million |
| Doxycycline monohydrate | 100% | Tier 2 | $43 million |
| Doxylamine succinate / pyridoxine hydrochloride | 0.2% | Tier 4 | no 2024 match |
| Drizalma (duloxetine) | 100% | Tier 4 | $1 million |
| Dronabinol | 100% | Tier 4 | $7 million |
| Drospirenone / ethinyl estradiol | 95.5% | Tier 2 | $571 thousand |
| Drospirenone / ethinyl estradiol / levomefolate calcium | 27.4% | Tier 2 | no 2024 match |
| Droxia (hydroxyurea) | 87.3% | Tier 4 | $165 thousand |
| Droxidopa | 76.4% | Tier 4 | $50 million |
| Duavee (bazedoxifene / estrogens, conjugated) | 66.5% | Tier 4 | $948 thousand |
| Dulera (formoterol fumarate / mometasone furoate) | 58.2% | Tier 3 | $162 million |
| Duloxetine | 100% | Tier 2 | $309 million |
| Duobrii (halobetasol propionate / tazarotene) | 0.4% | Tier 5 | $794 thousand |
| Duopa (carbidopa / levodopa) | 1% | Tier 4 | $3 million |
| Dupixent (dupilumab) | 100% | Tier 5 | $2.5 billion |
| Durezol (difluprednate) | 0.4% | Tier 1 | $805 thousand |
| Dutasteride | 99.2% | Tier 2 | $31 million |
| Dutasteride / tamsulosin hydrochloride | 66.9% | Tier 4 | $9 million |
| Duvyzat (givinostat) | 4.2% | Tier 5 | $2 million |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans